Effect of targeted magnetic nanoparticles containing 5-FU on expression of bcl-2, bax and caspase 3 in nude mice with transplanted human liver cancer

World Journal of Gastroenterology

Volumn 13, Issue 23, 2007, Pages 3171-3175

  Wang, Jian Ming ^a   Xiao, Bao Lai ^a   Zheng, Jian Wei ^a   Chen, Hai Bing ^b   Zou, Sheng Quan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Bax; Bcl 2; Caspase 3; Fluorouracil; Hepatocellular carcinoma; Magnetic nanoparticles

Indexed keywords

CASPASE 3; FLUOROURACIL; MAGNETIC NANOCARRIER; MESSENGER RNA; NANOCARRIER; PROTEIN BAX; PROTEIN BCL 2; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SIZE; CANCER TISSUE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAGNETIC FIELD; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 34447559603     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i23.3171     Document Type: Article

References (27)

1. Widder KJ, Morris RM, Poore GA, Howard DP, Senyei AE. Selective targeting of magnetic albumin microspheres containing low-dose doxorubicin: total remission in Yoshida sarcoma-bearing rats. Eur J Cancer Clin Oncol 1983; 19: 135-139
2. Babincova M, Altanerova V, Lampert M, Altaner C, Machova E, Sramka M, Babinec P. Site-specific in vivo targeting of magnetoliposomes using extemally applied magnetic field. Z Naturforsch [C] 2000; 55: 278-281
3. Gong LS, Zhang YD, Liu S. Target distribution of magnetic albumin nanoparticles containing adriamycin in transplanted rat liver cancer model. Hepatobiliary Pancreat Dis Int 2004; 3: 365-368
4. Gupta PK, Hung CT. Magnetically controlled targeted chemotherapy. In: N Willmott and J Daly, eds. Microspheres and Regional Cancer Therapy. CRC Press, 1993: 71-116
5. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80: 827-841
6. Tang ZY, Sun FX, Tian J, Ye SL, Liu YK, Liu KD, Xue Q, Chen J, Xia JL, Qin LX, Sun SL, Wang L, Zhou J, Li Y, Ma ZC, Zhou XD, Wu ZQ, Lin ZY, Yang BH. Metastatic human hepatocellular carcinoma models in nude mice and cell line with metastatic potential. World J Gastroenterol 2001; 7: 597-601
7. Shuto T, Kinoshita H, Hirohashi K, Kubo S, Tanaka H, Tsukamoto T, Okuda T. Indications for, and effectiveness of, a second hepatic resection for recurrent hepatocellnlar carcinoma. Hepatogastroenterology 1996; 43: 932-937
8. Blum HE. Molecular targets for prevention of hepatocellular carcinoma. Dig Dis 2002; 20: 81-90
9. Kogure T, Ueno Y, Iwasaki T, Shimosegawa T. The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol 2004; 53: 296-304
10. Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, Mizushima T, Ochi K, Kiura K, Tanimoto M. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 2003; 23: 1891-1897
11. Pohl J, Zuna I, Stremmel W, Rudi J. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellnlar carcinoma. Chemotherapy 2001; 47: 359-365
12. Murata K, Shiraki K, Kawakita T, Yamamoto N, Okano H, Nakamura M, Sakai T, Deguchi M, Ohmori S, Nakano T. Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res 2003; 23: 1719-1722
13. Dizon DS, Kemeny NE. Intrahepatic arterial infusion of chemotherapy: clinical results. Semin Oncol 2002; 29: 126-135
14. Xu H, Song T, Bao XQ. Site-directed research of magnetic nanoparticles in magnetic drug targeting. Journal of Magnetism and Magnetic Materials 2005; 293: 514-519.
15. Lubbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, Huhn D. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res 1996; 56: 4694-4701
16. Andrew DG, Giles R. Mathematical modeling of magnetically targeted drug delivery. Magnetism and Magnetic Materials 2005; 293: 455-463
17. Lubbe AS, Alexiou C, Bergemann C. Clinical applications of magnetic drug targeting. J Surg Res 2001; 95: 200-206
18. Zhang YD, Gong LS, Pan YF. Target distribution of magnetic nanoparticle containing drug in vivo and its therapeutical efficiency for liver cancer. Zhongguo Yixue Gongcheng Zazhi 2003; 11: 18-21
19. Clark JW, Glicksman AS, Wanebo HJ. Systemic and adjuvant therapy for patients with pancreatic carcinoma. Cancer 1996; 78: 688-693
20. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-2026
21. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59: 734-741
22. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-1326
23. Sartorius UA, Krammer PH. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 2002; 97: 584-592
24. Cohen-Saidon C, Razin E. The involvement of Bcl-2 in mast cell apoptosis. Novartis Found Symp 2005; 271: 191-195; discussion 195-199
25. Duan XX, Ou JS, Li Y, Su JJ, Ou C, Yang C, Yue HF, Ban KC. Dynamic expression of apoptosis-related genes during development of laboratory hepatocellular carcinoma and its relation to apoptosis. World J Gastroenterol 2005; 11: 4740-4744
26. Boyce M, Degterev A, Yuan J. Caspases: an ancient cellular sword of Damocles. Cell Death Differ 2004; 11: 29-37
27. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462